Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CG-7321
- Development stage
- Phase 1
- Lead developer
- Chengdu Saijing Biopharmaceutical Technology
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
CG-7321 is an orally bioavailable small molecule inhibitor targeting cyclin-dependent kinases 4 and 6 (CDK4/6), developed by Chengdu Saijing Biomedical Technology. By selectively inhibiting CDK4 and CDK6, the drug prevents the phosphorylation of the retinoblastoma (Rb) protein, thereby blocking cell cycle progression from the G1 to the S phase. This mechanism is particularly effective in treating hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative (HER2-) breast cancers, where the CDK4/6-cyclin D-Rb pathway is frequently overactive. CG-7321 is currently undergoing Phase 1 clinical evaluation for the treatment of advanced solid tumors and breast cancer.
02
Targets
CDK4 (Cyclin-dependent kinase 4)CDK6 (Cyclin-dependent kinase 6)
Beyond the preview
Go deeper on CG-7321.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CG-7321.